Surefire Medical has secured the CE Mark from European regulators for its new precision targeted delivery infusion system for direct-to-tumor embolization procedures.

Clinical trials are underway to add more medical conditions to Surefire’s infusion systems, which are currently used to treat inoperable liver cancers.

Surefire Medical president and CEO James E. Chomas said: "This product with its improved trackability will enable significant growth opportunities for Surefire Medical in the large worldwide primary liver cancer market.

"The rapidly growing body of clinical evidence indicates greater drug penetration into tumors with the unique Surefire infusion systems, which addresses a clear need in a treatment of primary liver cancer that can bridge patients to a liver transplant or extend their life by suppressing tumor growth."

Around 2.2 million people are being killed due to liver cancer across the world every year.

As per the figures released by the Centers for Disease Control and Prevention, the liver cancer death rate in the US doubled between 1981 and 2010, from eight to 16.3 deaths per 100,000 people.

With approximately 80% of liver cancers being inoperable, most patients are being treated with a minimally invasive embolization procedure performed by an interventional radiologist.